Pharmaceutical Technology

APRIL 3, 2023

Innate Pharma has signed an exclusive licence agreement with Takeda to enable research and development of antibody drug conjugates (ADCs) against an undisclosed target, primarily focusing on coeliac disease. In addition, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence.

Development 130

Development Antibody Pharma Production Engineer 130

pharmaphorum

FEBRUARY 8, 2022

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty. Pfizer shares actually fell in the wake of its results announcement as some analysts had been forecasting higher sales for Comirnaty this year.

Sales 98

Sales Vaccination Vaccine Antibody 98

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The collaboration is focused on developing anti-GPCR antibodies, which enable the creation of new treatments for autoimmune and inflammatory diseases.

Research 130

Research Antibody Sales Development 130

pharmaphorum

AUGUST 6, 2021

billion from sales of just under 200 million doses of its COVID-19 vaccine, taking its tally since approval to around $6 billion from 302 million shots. Moderna is now predicting sales of $20 billion for 2021 as a whole from up to 1 billion doses delivered, which compares to Pfizer estimate of $33.5 Moderna made a massive $4.2

Sales 105

Sales Vaccination Vaccine Antibody 105

pharmaphorum

JUNE 23, 2021

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1 billion takeover of Tesaro in 2019.

Sales 100

Sales Vaccination Vaccine Drugs 100

Pharmaceutical Technology

MAY 8, 2023

Ei s ai and Bliss Biopharmaceutical have entered into a joint development agreement for antibody-drug conjugate (ADC), BB-1701, to treat cancers. BB-1701 comprises anti-HER2 antibody and eribulin and has a unique mechanism of action (MOA) including potent bystander effect and immunogenic cell death (ICD) activity.

Development 246

Development Antibody Clinical Trials Clinical Trials 246

Pharmaceutical Technology

SEPTEMBER 2, 2022

lenalidomide) + a steroid ± an anti-CD38 antibody. Last month, the European Medicines Agency's (EMA) approval of Johnson & Johnson’s (J&J) anti-CD3/BCMA bispecific antibody Tecvayli (teclistamab) marked the fourth anti-BCMA biologic to enter the R/R MM market. Should CAR-T cells, or antibodies be used first?

Antibody 147

Antibody Sales FDA Approval Production 147

pharmaphorum

FEBRUARY 14, 2022

A recent report has found that R&D productivity rose vertiginously during 2021, but how much of this was organic and how much can be attributed to the pandemic? As a result, the estimated peak sales of assets increased from $360 million to $521 million in 2019 and 2021, respectively. In 2020, the development cycle averaged 7.14

Production 98

Production Clinical Trials Clinical Trials Sales 98

pharmaphorum

OCTOBER 18, 2022

Gilead Sciences has made yet another rush into the oncology category, licensing a bispecific antibody from MacroGenics in development as a treatment for CD123-positive blood cancers, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Along with the signing fee, there is another $1.7 It brought in $4.7

Antibody 52

Antibody Sales Clinical Trials Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 8, 2023

Despite receding sales, Comirnaty, its partnered COVID-19 vaccine with BioNTech, is still forecast to reach the analyst consensus global forecast sales of $33 billion for 2022, according to GlobalData’s Drugs Database Pharma Intelligence Center. billion on Dec 31, 2022. Merck & Co. billion to $281.3 and 31.6%, respectively.

Marketing 195

Marketing Sales Vaccination Vaccine 195

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. INDIANAPOLIS and THOUSAND OAKS, Calif. Reese , M.D.,

Antibody 52

Antibody Manufacturing Production Sales 52

Pharmaceutical Technology

DECEMBER 23, 2022

Merck (MSD outside North America) has signed an exclusive licence and partnership agreement with Kelun-Biotech for developing seven investigational preclinical antibody-drug conjugates (ADC) to treat cancer. Kelun-Biotech is entitled to get payments of up to $9.3bn in the future on meeting development, regulatory and sales milestones.

Development 130

Development Sales Production Antibody 130

Pharmaceutical Technology

MAY 19, 2023

Whilst there is a range of FDA-approved biologics for Crohn’s disease, Rinvoq is the first approved oral product for the moderate to severe type of the disease. AbbVie anticipates Rinvoq sales to exceed $7.5bn in 2025 and for the peak revenues from both drugs to exceed Humira’s peak sales by 2027.

FDA Approval 264

FDA Approval Dermatology Sales Clinical Trials 264

Pharmaceutical Technology

DECEMBER 19, 2022

With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate. On choosing the candidate, the company will oversee the complete development, production and marketing.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

Pharmaceutical Technology

MARCH 10, 2023

Freeze drying is a crucial technique to prolong the shelf life of pharmaceutical products. Also known as lyophilisation, the technique stabilises and preserves sensitive products such as biologics, and diagnostic kits, in a permanently storable state. The process eliminates the disadvantages of conventional drying methods or freezing.

Manufacturing 147

Manufacturing Production Containment Antibody 147

pharmaphorum

AUGUST 21, 2020

Doctors have called for rules to be tightened on coronavirus antibody tests in the UK amid fears that false readings could put the public at risk. It’s not even known for sure that having antibodies against the SARS-CoV-2 coronavirus confers immunity. Feature image courtesy of Rocky Mountain Laboratories/NIH.

Doctor 76

Doctor Doctors Antibody Marketing 76

Pharmaceutical Technology

APRIL 3, 2023

BioNTech has signed exclusive licence and collaboration agreements with Duality Biologics (DualityBio) for the development of two antibody-drug conjugate (ADC) assets for solid tumours. Once developed, the ADCs will join BioNTech’s existing portfolio of oncology products.

Development 246

Development Sales Antibody Manufacturing 246

The Pharma Data

SEPTEMBER 11, 2021

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. About Twist Bioscience Corporation.

Antibody 52

Antibody DNA Containment Manufacturing 52

Pharmaceutical Technology

SEPTEMBER 15, 2022

The increase in the production of biological drugs such as vaccines, gene and cell therapies, and monoclonal antibodies, is increasing the volume of injectable drug products in the global healthcare market. Discover the top commercial dose injectables companies in contract marketing. Factors driving the demand for injectables.

Marketing 130

Marketing Containment Production Sales 130

pharmaphorum

AUGUST 19, 2022

If approved, garadicimab will slot into CSL’s product line alongside two C1 esterase inhibitor medicines, namely Berinert which is administered by intravenous injection to treat HAE attacks, and Haegarda which is given twice-weekly as a subcutaneous injection for prevention. It is administered as an intravenous injection.

Antibody 52

Antibody Sales FDA Approval Genetics 52

Pharmaceutical Technology

MAY 8, 2023

Shanghai Junshi Biosciences and Dr. Reddy’s Laboratories have partnered for the development and commercialisation of the anti-PD-1 monoclonal antibody, toripalimab, in 21 countries. upfront payment, potential expansion of Dr. Reddy’s Territory and milestone payment, along with royalties on the net sales of the products comprising toripalimab.

Development 130

Development Marketing Licensing Licensing 130

The Pharma Data

APRIL 12, 2023

Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement Biogen Inc. Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ).

Antibody 40

Antibody Development Engineer Licensing 40

The Pharma Data

JANUARY 12, 2021

million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 TARRYTOWN, N.Y. , 12, 2021 /PRNewswire/ — . million doses.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52

Pharmaceutical Technology

AUGUST 18, 2022

Atomwise is also eligible to receive additional research, development and sales-based milestone payments totalling to over $1bn. Furthermore, Sanofi will make tiered royalty payments on products that are developed under this partnership. These targets will be exclusive to Sanofi.

Drugs 246

Drugs Engineer Medicine Sales 246

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. “As

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

XTalks

FEBRUARY 8, 2021

While the approval pathway for biosimilar products was established 12 years ago, there are still misconceptions about how biosimilars are approved, biosimilarity versus interchangeable status and which patients can be treated with biosimilars. What is an Interchangeable Biological Product? What is a Biosimilar?

Production 57

Production Insulin Branding Generic Drugs 57

Pharmaceutical Technology

JANUARY 3, 2023

The second programme involves the development of a new bispecific antibody with potential applications in solid tumours using Alligator’s Ruby platform. Alligator is entitled to receive milestone payments of up to $500.78m (€469m) for the development, approval, and sales of the three potential programmes.

Research 130

Research Development Sales Production 130

Pharmaceutical Technology

NOVEMBER 18, 2022

Under the deal, the companies will work together on the discovery activities for identifying and validating the conditionally active bispecific antibodies. This collaboration will use Regeneron’s Veloci-Bi bispecific antibody development platform and CytomX's Probody therapeutic platform.

Development 130

Development Antibody Licensing Licensing 130

Pharmaceutical Technology

JANUARY 19, 2023

However, it is possible to target CD33 in the clinic, as evidenced by the FDA approval of Pfizer’s anti-CD33 antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin) in 2000. GlobalData’s Pharma Intelligence Center shows 19 autologous CAR-T cell products in Phase I, and nine products in Phase II, globally.

Marketing 130

Marketing Gene Editing Production Sales 130

Pharmaceutical Technology

MAY 25, 2023

Yuflyma is a recombinant fully human anti–tumour necrosis factor α (anti-TNFα) monoclonal antibody. As a leading global biopharmaceutical company, we are leveraging our unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to expand the availability of high-quality biosimilars for US patients.”

FDA Approval 130

FDA Approval Packaging Packaging Clinical Trials 130

The Pharma Data

DECEMBER 29, 2020

First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. futility analysis).

Antibody 52

Antibody Trials Production Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 22, 2023

The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. Since April 2020, Sanofi is responsible for Praluent outside of the US, while Regeneron handles its sale in the US.

Antibody 262

Antibody Drugs Protein Sales 262

Pharmaceutical Technology

DECEMBER 7, 2022

Additionally, AbbVie could make commercial milestone and tiered royalty payments on global net sales in the future to HotSpot. On AbbVie exercising its licencing option, the company will be responsible for carrying out all clinical development, production and marketing works of the IRF5 inhibitor programme in the future.

Development 147

Development Clinical Development Sales Antibody 147

Pharmaceutical Technology

SEPTEMBER 28, 2022

Seagen also will make potential development, regulatory and commercial milestone payments of up to nearly $650m, as well as royalty payments on the sales of the product in the future. Under this deal, Seagen also holds an option for nominating up to two more tumour targets for biospecifics leveraging the Gammabody platform.

Development 130

Development Licensing Licensing Production 130

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. This figure derives from net product sales in addition to revenues gained from royalties and licensing agreements. compound annual growth rate (CAGR) according to Pfizer’s risk-adjusted projection.

Licensing 147

Licensing Licensing Sales Trials 147

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

Roots Analysis

FEBRUARY 26, 2024

Having reported over 70% increase in revenues over the past 5-6 years, the market for biologically derived products is currently estimated to be worth more than USD 200 billion. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52